317 related articles for article (PubMed ID: 20626746)
1. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.
Berger J; Pujol A; Aubourg P; Forss-Petter S
Brain Pathol; 2010 Jul; 20(4):845-56. PubMed ID: 20626746
[TBL] [Abstract][Full Text] [Related]
2. Therapy of X-linked adrenoleukodystrophy.
Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
[TBL] [Abstract][Full Text] [Related]
3. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
4. Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
Cappa M; Bizzarri C; Giannone G; Aiello C; Di Biase A
J Endocrinol Invest; 2011 Nov; 34(10):753-6. PubMed ID: 21399389
[TBL] [Abstract][Full Text] [Related]
5. Therapy of X-linked adrenoleukodystrophy.
Moser HW
NeuroRx; 2006 Apr; 3(2):246-53. PubMed ID: 16554262
[TBL] [Abstract][Full Text] [Related]
6. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
7. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of very long-chain fatty acids levels in X-linked adrenoleukodystrophy, treated with haematopoietic stem cell transplantation and Lorenzo's Oil.
Stradomska TJ; Drabko K; Moszczyńska E; Tylki-Szymańska A
Folia Neuropathol; 2014; 52(2):159-63. PubMed ID: 25118901
[TBL] [Abstract][Full Text] [Related]
9. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.
Moser HW
J Neuropathol Exp Neurol; 1995 Sep; 54(5):740-5. PubMed ID: 7666063
[TBL] [Abstract][Full Text] [Related]
10. Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.
Sassa T; Wakashima T; Ohno Y; Kihara A
J Lipid Res; 2014 Mar; 55(3):524-30. PubMed ID: 24489110
[TBL] [Abstract][Full Text] [Related]
11. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients.
Jang J; Kang HC; Kim HS; Kim JY; Huh YJ; Kim DS; Yoo JE; Lee JA; Lim B; Lee J; Yoon TM; Park IH; Hwang DY; Daley GQ; Kim DW
Ann Neurol; 2011 Sep; 70(3):402-9. PubMed ID: 21721033
[TBL] [Abstract][Full Text] [Related]
12. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.
Deon M; Garcia MP; Sitta A; Barschak AG; Coelho DM; Schimit GO; Pigatto M; Jardim LB; Wajner M; Giugliani R; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):43-9. PubMed ID: 18026827
[TBL] [Abstract][Full Text] [Related]
13. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
[TBL] [Abstract][Full Text] [Related]
14. The X-linked adrenoleukodystrophy (X-ALD) and oxidative stress.
Al-Omar MA
J Herb Pharmacother; 2006; 6(3-4):125-34. PubMed ID: 17317654
[TBL] [Abstract][Full Text] [Related]
15. [Endocrine disease in adrenoleukodystrophy].
Girard S; Bruckert E; Turpin G
Ann Med Interne (Paris); 2001 Feb; 152(1):15-26. PubMed ID: 11240421
[TBL] [Abstract][Full Text] [Related]
16. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients.
Pai GS; Khan M; Barbosa E; Key LL; Craver JR; Curé JK; Betros R; Singh I
Mol Genet Metab; 2000 Apr; 69(4):312-22. PubMed ID: 10870849
[TBL] [Abstract][Full Text] [Related]
18. Lorenzo's oil may help to prevent ALD symptoms.
Senior K
Lancet Neurol; 2002 Dec; 1(8):468. PubMed ID: 12849323
[No Abstract] [Full Text] [Related]
19. Dietary management of X-linked adrenoleukodystrophy.
Moser HW; Borel J
Annu Rev Nutr; 1995; 15():379-97. PubMed ID: 8527226
[TBL] [Abstract][Full Text] [Related]
20. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
